Deep mutagenesis scanning using whole trimeric SARS-CoV-2 spike highlights the importance of NTD-RBD interactions in determining spike phenotype

New variants of SARS-CoV-2 are continually emerging with mutations in spike associated with increased transmissibility and immune escape. Phenotypic maps can inform the prediction of concerning mutations from genomic surveillance, however most of these maps currently derive from studies using monomeric RBD, while spike is trimeric, and contains additional domains. These maps may fail to reflect interdomain interactions in the prediction of phenotypes. To try to improve on this, we developed a platform for deep mutational scanning using whole trimeric spike. We confirmed a previously reported epistatic effect within the RBD affecting ACE2 binding, that highlights the importance of updating the base spike sequence for future mutational scanning studies. Using post vaccine sera, we found that the immune response of vaccinated individuals was highly focused on one or two epitopes in the RBD and that single point mutations at these positions can account for most of the immune escape mediated by the Omicron BA.1 RBD. However, unexpectedly we found that the BA.1 RBD alone does not account for the high level of antigenic escape by BA.1 spike. We show that the BA.1 NTD amplifies the immune evasion of its associated RBD. BA.1 NTD reduces neutralistion by RBD directed monoclonal antibodies, and impacts ACE2 interaction. NTD variation is thus an important mechanism of immune evasion by SARS-CoV-2. Such effects are not seen when pre-stabilized spike proteins are used, suggesting the interdomain effects require protein mobility to express their phenotype.

[1]  P. Bieniasz,et al.  Molecular fate-mapping of serum antibody responses to repeat immunization , 2023, Nature.

[2]  Peng Wang,et al.  Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution , 2022, bioRxiv.

[3]  Timothy C. Yu,et al.  A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike , 2022, Cell.

[4]  A. Walls,et al.  Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains , 2022, bioRxiv.

[5]  J. Zahradník,et al.  Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5 , 2022, Cell.

[6]  A. Shepherd,et al.  Evolutionary remodelling of N‐terminal domain loops fine‐tunes SARS‐CoV‐2 spike , 2022, EMBO reports.

[7]  O. Pybus,et al.  Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa , 2022, Nature Medicine.

[8]  Kenneth A. Matreyek,et al.  Probing the biophysical constraints of SARS-CoV-2 spike N-terminal domain using deep mutational scanning , 2022, bioRxiv.

[9]  B. Meng,et al.  SARS-CoV-2 spike N-terminal domain modulates TMPRSS2-dependent viral entry and fusogenicity , 2022, bioRxiv.

[10]  Thomas H. Segall-Shapiro,et al.  Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein , 2022, bioRxiv.

[11]  Kenneth A. Matreyek,et al.  Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution , 2022, bioRxiv.

[12]  E. Wherry,et al.  Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals , 2022, Cell.

[13]  Frances E. Muldoon,et al.  Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity , 2022, Nature.

[14]  Mark M. Davis,et al.  Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination , 2022, Cell.

[15]  T. Ndung’u,et al.  SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape , 2022, Cell Host & Microbe.

[16]  J. Ball,et al.  In vitro evolution predicts emerging SARS-CoV-2 mutations with high affinity for ACE2 and cross-species binding , 2021, bioRxiv.

[17]  T. Ndung’u,et al.  Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization , 2021, Nature.

[18]  Fei Shao,et al.  Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies , 2021, bioRxiv.

[19]  M. Kraemer,et al.  Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa , 2021, Nature.

[20]  E. Wherry,et al.  Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals , 2021, medRxiv.

[21]  M. Koopmans,et al.  The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology , 2021, Nature Medicine.

[22]  G. Barton,et al.  Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics , 2021, eLife.

[23]  Rommie E. Amaro,et al.  SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma , 2021, Proceedings of the National Academy of Sciences.

[24]  O. Dym,et al.  SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution , 2021, Nature Microbiology.

[25]  S. Singh,et al.  SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India , 2021, Microorganisms.

[26]  J. Bloom,et al.  Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection , 2021, Science Translational Medicine.

[27]  William T. Harvey,et al.  SARS-CoV-2 variants, spike mutations and immune escape , 2021, Nature Reviews Microbiology.

[28]  J. Skehel,et al.  Evolution of the SARS-CoV-2 spike protein in the human host , 2021, Nature Communications.

[29]  Adam S. Dingens,et al.  Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016 , 2021, Cell Reports Medicine.

[30]  Ilya J. Finkelstein,et al.  Rapid characterization of spike variants via mammalian cell surface display , 2021, bioRxiv.

[31]  A. Godzik,et al.  Detection of a SARS-CoV-2 variant of concern in South Africa , 2021, Nature.

[32]  Sergei L. Kosakovsky Pond,et al.  Detection of a SARS-CoV-2 variant of concern in South Africa , 2021, Nature.

[33]  J. Lebbink,et al.  Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants , 2021, bioRxiv.

[34]  Adam S. Dingens,et al.  Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016 , 2021, bioRxiv.

[35]  E. Procko,et al.  An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants , 2021, Science Advances.

[36]  Graham W. Taylor,et al.  SARS-CoV-2 evolution during treatment of chronic infection , 2021, Nature.

[37]  J. Bloom,et al.  Prospective mapping of viral mutations that escape antibodies used to treat COVID-19 , 2021, Science.

[38]  M. Beltramello,et al.  N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 , 2021, bioRxiv.

[39]  D. Ho,et al.  Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite , 2021, bioRxiv.

[40]  J. Bloom,et al.  Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies , 2021, bioRxiv.

[41]  J. Bloom,et al.  Prospective mapping of viral mutations that escape antibodies used to treat COVID-19 , 2020, bioRxiv.

[42]  Mitchell H. Murdock,et al.  mGreenLantern: a bright monomeric fluorescent protein with rapid expression and cell filling properties for neuronal imaging , 2020, Proceedings of the National Academy of Sciences.

[43]  Gaurav D. Gaiha,et al.  Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host , 2020, The New England journal of medicine.

[44]  E. Fischer,et al.  Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer , 2020, Cell.

[45]  E. Procko,et al.  An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants , 2020, bioRxiv.

[46]  Sarah K. Hilton,et al.  Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding , 2020, Cell.

[47]  J. Dye,et al.  Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2 , 2020, Science.

[48]  Shuwen Liu,et al.  Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 , 2020, Acta Pharmacologica Sinica.

[49]  G. Ippolito,et al.  Structure-based design of prefusion-stabilized SARS-CoV-2 spikes , 2020, Science.

[50]  Jie Zhou,et al.  Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice , 2020, Nature Communications.

[51]  Jie Zhou,et al.  Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice , 2020, Nature Communications.

[52]  R. Welsh,et al.  Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail , 2020, Science.

[53]  Linqi Zhang,et al.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.

[54]  Diwakar Shukla,et al.  Structural architecture of a dimeric class C GPCR based on co-trafficking of sweet taste receptor subunits , 2019, The Journal of Biological Chemistry.

[55]  M. E. Francis,et al.  Back to the Future for Influenza Preimmunity—Looking Back at Influenza Virus History to Infer the Outcome of Future Infections , 2019, Viruses.

[56]  E. Procko,et al.  Mapping Interaction Sites on Human Chemokine Receptors by Deep Mutational Scanning , 2018, The Journal of Immunology.

[57]  F. Ferrara,et al.  Pseudotype Neutralization Assays: From Laboratory Bench to Data Analysis , 2018, Methods and protocols.

[58]  J. Bloom,et al.  Comprehensive Mapping of HIV-1 Escape from a Broadly Neutralizing Antibody. , 2017, Cell host & microbe.

[59]  Marten Postma,et al.  mScarlet: a bright monomeric red fluorescent protein for cellular imaging , 2016, Nature Methods.

[60]  Jesse D. Bloom,et al.  An Experimentally Determined Evolutionary Model Dramatically Improves Phylogenetic Fit , 2014, bioRxiv.

[61]  Bartek Wilczynski,et al.  Biopython: freely available Python tools for computational molecular biology and bioinformatics , 2009, Bioinform..